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CASE REPORT
Treatment of Linear Morphea (en Coup de Sabre) with 
Micronized Acellular Dermal Matrix Filler: A Case Report
Jemin Kim1,2, Jihee Kim1,2, Young In Lee1,2, Ju Hee Lee1,2
1Department of Dermatology and Cutaneous Biology Research Institute, Severance Hospital, Yonsei University College of Medicine, 
2Scar Laser and Plastic Surgery Center, Yonsei Cancer Hospital, Seoul, Korea
En coup de sabre variant of linear morphea (LM) is a rare scle-
rotic skin disorder characterized by disfiguring linear depres-
sion of the frontal or frontoparietal forehead. Current at-
tempts for cosmetic correction of atrophic lesions must be 
preceded by an evaluation of disease activity of LM, either by 
a sufficient clinical assessment or histologic evidence. Cor-
rective procedures including corrective surgery, autologous 
fat grafting, hyaluronic acid filler injections were performed 
with varying degrees of success; still, there is a need for treat-
ment options with non-invasive and long-term maintenance 
effects. Herein we report the use of micronized acellular der-
mal matrix filler as a novel and successful treatment for the 
atrophic defect of LM in a 24-year-old female. Molecular 
characteristics of the micronized acellular dermal matrix fill-
er give enhanced durability and prolonged volume con-
sistency, which results in a long-term extracellular matrix re-
modeling effect. (Ann Dermatol 33(4) 373∼376, 2021)
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INTRODUCTION
Linear morphea (LM) is a rare localized variant of scle-
roderma, and the term “en coup de sabre” (ECDS) refers to 
atrophic linear depression of the frontal or frontoparietal 
forehead extending to the scalp. The underlying etiology 
of LM is still poorly understood, although some have sug-
gested that morphea represents a mosaic form of systemic 
sclerosis limited to the skin1. LM may have a self-limited 
course, but it frequently has a relapsing or chronic nature 
despite aggressive medical treatments during the active 
phase of the disease. Moreover, delayed diagnosis and sub-
sequent permanent cosmetic sequelae are common, espe-
cially for adult-onset LM2.
Cosmetic correction of LM with a residual atrophic scar 
involves the use of invasive techniques, such as corrective 
surgery, autologous fat grafting, and placement of synthetic 
tissue matrix, which has been performed with varying de-
grees of success3. However, considering the potential risk 
of re-triggering LM by surgical trauma, there is a need for 
minimally invasive techniques with appropriate timing of 
intervention. Herein, we describe the use of micronized 
acellular dermal matrix filler as a novel and successful 
treatment for the atrophic defect of LM. We received a 
consent form from the patient about publishing the photo-
graphic materials.
CASE REPORT
A 24-year-old female presented to our clinic with a linear 
vertical depression on the left medial forehead that ex-
tended to the scalp (Fig. 1A, C). The area was asympto-
matic, and she did not remember the exact onset of the 
disease, but she reported that the lesion had been gradu-
ally progressing for about 1 year. There were no asso-
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Fig. 1. (A) Linear vertical depres-
sion was present on the left medial 
forehead at the initial visit, (B) sus-
tained improvement was achieved 
at 6 months post-injection. (C) 
Lateral view of patient at baseline, 
(D) 6 months post-injection. 
Fig. 2. (A) Irregularly thickened 
collagen bundles in the mid dermis 
and (B) subcutaneous fat. Note that 
inflammatory infiltrates were sparse, 
indicating the inactive phase of 
linear morphea (H&E, ×100).
ciated skull, ophthalmologic, or neurologic abnormalities, 
and she had normal laboratory values, including a neg-
ative antinuclear antibody screen result. With the initial 
diagnosis being the ECDS variant of LM, we prescribed or-
al prednisolone (5∼10 mg/day) for 6 weeks followed by 
oral hydroxychloroquine (200 mg/day) for 6 months. After 
the medical treatments, the lesions remained stable with-
out signs of inflammation or spreading. A skin biopsy of 
the forehead-scalp boarder revealed epidermal atrophy 
along with increased sclerosis of the dermis and subcuta-
neous fat, confirming the inactive phase of LM (Fig. 2).
Since the patient was concerned about the cosmetic dis-
figuration, we attempted volumetric correction of the de-
pressions in the forehead region. With the patient under 
local anesthesia, we successfully injected 1 ml of a micro-
nized acellular dermal matrix filler (MegafillⓇ; L&C BIO, 
Seongnam, Korea) along two different planes: the periosteum 
and dermal-subcutaneous junction. Immediate improvement 
of the surface contour was noted, and no early or late 
complications developed postoperatively.
Six months following the injection, the depressed lesion 
was adequately augmented with a favorable aesthetic out-
come (Fig. 1B, D). With the aid of a three-dimensional skin 
analysis camera system (Antera 3D; Miravex, Dublin, Ireland), 
we were able to perform a quantitative assessment of the 
skin defect. The depressed volume of the forehead re-
markably decreased from 10.11 to 2.30 mm3, which was 
about an 80% improvement (Fig. 3).
We received the patient’s consent form about publishing 
all photographic materials.
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Fig. 3. (A) Baseline image was 
taken by the Antera camera (flat 
view) and (B) 6 months post-injec-
tion. The depressed volume within 
the area surrounded by the red 
dotted line was measured with 
depression mode in Antera camera 
(C) at the initial visit, (D) six months 
after the filler injection.
DISCUSSION
Soft tissue loss caused by the ECDS variant of LM results 
in disfiguring, permanent atrophy of the forehead and ad-
jacent scalp. The lack of proper indicators of disease activ-
ity and prognosis cause difficulties in determining the opti-
mal time for corrective procedures. Furthermore, even if 
the patient seems to be in a clinically quiescent disease 
phase, recurrence of the disease after corrective surgery is 
not uncommon1. Thus, treatment options with non-invasive 
and long-term maintenance effects are needed to mini-
mize the risk of re-activation of LM by iatrogenic trauma.
Autologous fat grafting has long been used for soft tissue 
augmentation of facial LM, and favorable cosmetic results 
with a mean maintenance duration of 43 months were re-
ported in the retrospective analysis by Roh et al4. Howev-
er, they also noted that multiple treatment sessions were 
needed (2∼11 sessions) owing to the high resorption rate 
of the injected fat. Besides, autologous fat grafting requires 
skilled practitioners to perform the procedure and a fa-
cility to store the extracted fat, which can cause increased 
medical costs.
Minimally invasive methods, such as hyaluronic acid (HA) 
filler, calcium hydroxyapatite filler, and poly-L-lactic acid 
filler, have been used in isolated case reports with varying 
degrees of success3,5,6. Among these options, the HA filler 
injection is considered to be the safest and relatively effec-
tive because of the stability of HA material in vivo and 
theoretical reversibility with hyaluronidase5. However, in-
jection of HA filler into the frontal area could result in a 
persistently visible blue hue, which can cause cosmetic 
concern7. Additionally, although rarely reported, HA can 
result in foreign body granuloma formation, tissue necrosis 
by vessel compression, and allergic reaction8.
The micronized acellular dermal matrix filler (MegafillⓇ) is 
produced after pulverizing the cross-linked human acel-
lular dermal matrix, and epidermal and dermal cellular com-
ponents are removed to preclude immunologic reactions 
and rejection9. The manufacturing process involves the 
cross-linking of collagen by using electron beams, which 
gives augmented mechanical strength and structural in-
tegrity to the filler material. Moreover, implantation of acell-
ular dermal matrix in an animal model revealed increased 
expressions of type I collagen, matrix metalloproteinases-1 
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(MMP-1), MMP-2, and transforming growth factor-ß for up 
to 6 months10. These molecular features result in enhanced 
durability and prolonged volume consistency of the mi-
cronized acellular dermal matrix filler not only by the vol-
umizing effect but also by the long-term extracellular ma-
trix remodeling effect. There was a case report of a LM pa-
tient who showed excellent cosmetic outcomes by acel-
lular dermal matrix (AlloDermⓇ; LifeCell Corp., Branchburg, 
NJ, USA) implantation11. However, we expect that MegafillⓇ 
filler has advantage over AlloDermⓇ because it is available 
in injectable formulation, allowing a minimally invasive 
technique.
In summary, we suggest that micronized acellular dermal 
matrix filler can be a less invasive and effective therapy for 
esthetic improvement of permanent atrophy caused by 
LM. Current attempts for cosmetic correction of atrophic 
lesions must be preceded by an evaluation of disease ac-
tivity of LM, either by a sufficient clinical assessment or 
histologic evidence. During the treatments, the use of the 
image analyzer technique for objective measurement of 
the depressed volume is helpful for evaluating the treat-
ment efficacy.
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